Khadija Saeed

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Eaton stock jumps on HSBC upgrade as data-center power demand grabs the tape

Eaton stock jumps on HSBC upgrade as data-center power demand grabs the tape

Eaton Corporation plc shares climbed roughly 3.6% to $345.36 in Friday afternoon trading following HSBC’s upgrade to Buy. The bank also lifted its price target on the power-management firm from $390 to $400. HSBC highlighted Eaton’s “diversified” portfolio and noted its clear “above-market growth prospects,” while downplaying concerns tied to recent softening in the AI supply chain.
Mastercard stock price slips as UK fee-cap ruling adds to pressure on payments giants

Mastercard stock price slips as UK fee-cap ruling adds to pressure on payments giants

Shares of Mastercard Incorporated slipped on Friday following a UK court decision that strengthened a regulator’s authority to cap certain cross-border card fees, adding to the growing list of policy risks facing payment networks. The stock dipped about 0.1% to $542.22 after earlier falling to $538.60. In London, a High Court judge dismissed Mastercard’s challenge, affirming that Britain’s Payments System Regulator can set price caps on interchange fees, though the exact limits and timeline remain undecided.
16 January 2026
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares jumped about 35% on Friday after the cancer drugmaker reported faster enrollment and stronger interim results in a key bladder cancer study for its ANKTIVA therapy. The stock was up $1.39 at $5.34 by 12:51 p.m. EST after hitting $5.53, with about 133 million shares traded. The company said more than 85% of patients are enrolled in its QUILT-2.005 trial and it is targeting a U.S. filing by the end of 2026; an interim analysis showed 85% of patients on ANKTIVA plus BCG stayed in complete response at six months versus 57% on BCG alone and 84% versus 52% at nine months.
1 483 484 485 486 487 893
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Uber

NYSE: UBER 93 / 100
#3 BUY ON WEAKNESS

Taiwan Semiconductor

NYSE: TSM 91 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 88 / 100
#5 BUY THE RESET

Ferguson

NYSE: FERG 86 / 100
View full portfolio
Editorial model selection. Not personalised advice.